Delayed Systemic Recurrence of Uveal Melanoma
- 1 October 2013
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 36 (5) , 443-449
Abstract
Context: Metastatic uveal melanoma recurrence after ≥10 years is not well studied in the clinical literature. This study describes the clinical characteristics and natural history of patients with delayed tumor recurrence. Objective: To describe the characteristics of patients with delayed systemic recurrence of uveal melanoma and the natural history of the disease after recurrence. Evidence Acquisition: This is a chart review of patients treated between 1994 and 2008 at The University of Texas, MD Anderson Cancer Center for uveal melanoma whose disease recurred ≥10 years after treatment of the primary tumor. Results: Of 463 patients treated for metastatic uveal melanoma, 305 developed systemic recurrence within 5 years from the time of diagnosis of primary melanoma, 97 developed systemic recurrences between 5 and 10 years, whereas 61 patients developed metastasis after ≥10 years. The interval between primary to first systemic metastasis was a significant independent predictor of survival time from first systemic metastasis. The median survival time for patients with delayed metastatic recurrence after ≥10 years was significantly longer than for patients who had intermediate or early systemic recurrence. Levels of lactate dehydrogenase, serum alkaline phosphatase, serum albumin, age, M-stage, and performance status at time of recurrence, as well as sex were also independent predictors of survival time from systemic recurrence. Conclusions: Longer time interval between primary and first systemic metastasis is significantly correlated with prolonged survival. Patients who survive ≥10 years without tumor metastasis after treatment for primary uveal melanoma cannot be considered cured. Prognosis remains poor for patients with metastatic uveal melanoma.Keywords
This publication has 33 references indexed in Scilit:
- METOncogene Inhibition as a Potential Target of Therapy for Uveal MelanomasInvestigative Ophthalmology & Visual Science, 2010
- Late recurrence (10 years or more) of malignant melanoma in south‐east Germany (Saxony) A single‐centre analysis of 1881 patients with a follow‐up of 10 years or moreJournal of the European Academy of Dermatology and Venereology, 2010
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- Oncogenic Mutations inGNAQOccur Early in Uveal MelanomaInvestigative Ophthalmology & Visual Science, 2008
- Models, mechanisms and clinical evidence for cancer dormancyNature Reviews Cancer, 2007
- Expression of Insulin-Like Growth Factor Receptor (IGF-1R), c-Fos, and c-Jun in Uveal Melanoma: An Immunohistochemical StudyCurrent Eye Research, 2006
- Variates of Survival in Metastatic Uveal MelanomaJournal of Clinical Oncology, 2005
- The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanomaBritish Journal of Plastic Surgery, 1989
- Late metastases (beyond ten years) of cutaneous malignant melanomaJournal of the American Academy of Dermatology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958